SUPPLEMENTARY DATA
for Parati G. et al. “CHANGES IN 24 HOUR AMBULATORY BLOOD PRESSURE AND
EFFECTS OF ANGIOTENSIN II RECEPTOR BLOCKADE DURING ACUTE AND
PROLONGED HIGH ALTITUDE EXPOSURE. A RANDOMIZED CLINICAL TRIAL.”
Index:
Table S1.
- page 2
Figure S1
- page 6
List of Expedition Participants
- page 7
List of Scientific Collaborators
- page 7
1
Table 1. Average systolic (SBP) and diastolic (DBP) blood pressure and heart rate (HR) values derived from conventional measurements and from
24 h ambulatory BP monitoring (ABPM) in telmisartan (N=20) and placebo group (N=25). ABPM data are separately shown for 24 hours,
daytime, night-time as well as for nocturnal dipping. All BP values are in mmHg; HR in beats per minute; nocturnal fall (dip) as percentage of
daytime mean level. All data are adjusted for baseline pre-treatment sea level values. BP and HR data are shown as least squares means ± standard
errors.
P values in the table refer to contrasts between groups for each condition. Symbols of statistical significance refer to contrasts of study conditions
vs. SLpost : *** p<0.001, ** p<0.01, * p<0.05
SBP
Conv.
24 h
Day
SLpost
Namche
BC1
BC2
SLret
Placebo
113.1±1.98
117.18±1.88
122.00±1.98***
121.50±1.88***
111.60±1.94
Telmisartan
113.66±2.15
115.49±2.11
126.39±2.11***
119.73±2.24
114.53±2.36
P value
0.848
0.651
0.277
0.651
0.626
Placebo
117.53±1.65
126.31±1.58***
131.19±1.58***
130.37±1.58***
118.67±1.58
Telmisartan
111.73±1.77
121.45±1.77***
131.41±1.77***
128.70±1.86***
116.59±1.80*
P value
0.026
0.058
0.926
0.543
0.500
Placebo
122.42±1.69
130.96±1.62***
135.00±1.62***
134.46±1.62***
123.13±1.62
Telmisartan
116.78±1.81
127.09±1.81***
136.81±1.81***
134.33±1.91***
121.22±1.84*
2
Night
Dip
DBP
Conv.
24 h
Day
P value
0.037
0.161
0.538
0.961
0.538
Placebo
106.09±1.87
115.10±1.80***
123.61±1.80***
121.97±1.80***
109.58±1.80
Telmisartan
101.51±2.01
108.99±2.01***
121.87±2.01***
117.44±2.12***
107.70±2.04**
P value
0.123
0.039
0.521
0.123
0.521
Placebo
13.45±1.03
12.37±0.98
8.62±0.98**
9.63±0.98*
11.36±0.98
Telmisartan
12.58±1.09
13.73±1.09
10.6±1.09
12.1±1.17
10.54±1.12
P value
0.631
0.503
0.328
0.290
0.631
Placebo
69.75±1.51
72.74±1.42
77.79±1.51***
75.58±1.42**
69.33±1.48
Telmisartan
68.62±1.63
68.9±1.59
77.98±1.59***
73.8±1.72
67.96±1.82
P value
0.887
0.189
0.932
0.788
0.887
Placebo
74.5±1.09
81.82±1.04***
84.16±1.04***
85.00±1.04***
75.71±1.04***
Telmisartan
69.4±1.17
77.26±1.17***
83.58±1.17***
82.5±1.23***
73.91±1.19***
P value
0.002
0.005
0.710
0.159
0.302
Placebo
78.91±1.17
86.47±1.12***
88.18±1.12***
89.08±1.12***
80.81±1.12
Telmisartan
73.97±1.26
82.06±1.26***
87.98±1.26***
87.72±1.32***
79.17±1.28***
0.007
0.013
0.905
0.473
0.397
P value
3
Night
Dip
HR
Conv.
24 h
Day
Night
Placebo
64.48±1.25
70.91±1.20***
76.46±1.20***
76.85±1.20***
65.52±1.20
Telmisartan
59.94±1.34
66.48±1.34***
75.94±1.34***
72.3±1.42***
63.73±1.36*
P value
0.019
0.019
0.773
0.019
0.383
Placebo
18.46±1.3
18.27±1.23
13.38±1.23*
14.06±1.23*
19.27±1.23
Telmisartan
18.2±1.37
18.4±1.37
13.36±1.37*
17.18±1.48
18.71±1.41
P value
0.991
0.991
0.991
0.345
0.991
Placebo
55.86±1.90
65.79±1.79***
71.4±1.89***
73.09±1.79***
57.86±1.86
Telmisartan
57.26±2.05
68.88±2.01***
70.54±2.01***
69.48±2.15***
61.31±2.27
P value
0.669
0.326
0.757
0.322
0.326
Placebo
66.23±1.67
78.54±1.60***
83.77±1.60***
80.77±1.60***
69.17±1.60
Telmisartan
67.26±1.79
77.78±1.79***
81.7±1.79***
80.37±1.89***
71.12±1.82
P value
0.800
0.817
0.552
0.872
0.552
Placebo
70.32±1.79
83.67±1.71***
90.72±1.71***
88.27±1.71***
73.56±1.71
Telmisartan
71.75±1.91
82.11±1.91***
87.79±1.91***
87.13±2.02***
75.82±1.95
P value
0.636
0.636
0.371
0.669
0.503
Placebo
57.06±1.85
66.83±1.77***
70.73±1.77***
66.52±1.77***
61.00±1.77.
4
Telmisartan
Dip
58.11±1.98
67.42±1.98***
70.58±1.98***
67.29±2.09***
62.18±2.02
P value
0.894
0.894
0.956
0.894
0.894
Placebo
18.9±1.51
20.52±1.43
22.48±1.43
24.65±1.43*
16.90±1.43
Telmisartan
18.61±1.60
17.63±1.60
19.61±1.60
22.31±1.71
17.49±1.63
0.895
0.465
0.465
0.546
0.851
P value
5
Figure S1. Changes in SBP (upper panels) and DBP (lower panels) nocturnal dipping size (higher
number meaning larger nocturnal dip) between baseline (SLpost) and BC1 (left panels) or BC2
(right panels) in subjects with reduced (blue) versus optimal (red) sleep quality.
Quality of sleep reduced
Quality of sleep optimal
Quality of sleep reduced
Quality of sleep optimal
Quality of sleep reduced
Quality of sleep optimal
Quality of sleep reduced
Quality of sleep optimal
6
HIGHCARE-HIMALAYA Expedition Participants (investigators and volunteers):
Piergiuseppe Agostoni, Manuela Bartesaghi, Alberto Bianchi, Barbara Bilo, Grzegorz Bilo, Daniele
Bonacina, Maurizio Bussotti, Gianluca Caldara, Andrea Cappugi, Tiziano Colombo, Francesca
Contini, Gianluca Croci, Andrea Faini, Rossana Figini, Andrea Giuliano, Francesca Gregorini,
Frederic Julliet, Elena Kaschina, Carolina Lombardi, Veronica Mainini, Elena Martinelli, Elena
Mascheroni, Susanna Mastrobuoni, Paolo Mazzoleni, Paolo Meriggi, Pietro Amedeo Modesti,
Marco Morabito, Ilario Mostachetti, Gianfranco Parati, Alberto Piperno, Barbara Poletti, Stefano
Rapi, Miriam Revera, Giovanni Romanini, Mauro Romerio, Luciano Sangalli, Giulio Savia,
Katarzyna Styczkiewicz, Margherita Tamplenizza
HIGHCARE-HIMALAYA Scientific Collaborators:
Athanasios Benetos (Nancy, France), Andrea Biondi (Milan, Italy), Pierre Boutouyrie (Paris,
France), Giovanna Branzi (Milan, Italy), Paolo Castiglioni (Milan, Italy), Alfonso Crisci (Florence,
Italy), Marco Di Rienzo (Milan, Italy), Marzia Galli-Kienle (Milan, Italy), Kalina Kawecka-Jaszcz
(Krakow, Poland), Liu Lisheng (Beijing, China), Stéphane Laurent (Paris, France), Fulvio Magni
(Milan, Italy), Gabriella Malfatto (Milan, Italy), Giuseppe Mancia (Milan, Italy), Thomas Unger
(Berlin, Germany), Mariaconsuelo Valentini (Milan, Italy), Alberto Zanchetti (Milan, Italy)
7